Valproic Acid and DHA Combination for Coronavirus Replication Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral strategies for coronavirus infections, such as COVID-19, are inadequate in efficacy and accessibility, necessitating the development of affordable and broadly effective therapeutics.
Innovation Solution
Administering therapeutically effective doses of valproic acid and docosahexaenoic acid to subjects to inhibit coronavirus replication and reduce symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiviral strategies are used, then treatment is available, but efficacy is inadequate
Solution Approach 1:
The patent combines valproic acid (VPA) and docosahexaenoic acid (DHA) into a single therapeutic regimen. VPA inhibits histone deacetylases to increase antiviral interferon expression, while DHA incorporates into viral membranes to disrupt replication. This merging of two distinct mechanisms of action produces synergistic antiviral effects that overcome the limitations of single-agent therapies.
Solution Approach 2:
The treatment approach uses a composite therapeutic strategy combining two chemically distinct compounds with different mechanisms of action. VPA is a histone deacetylase inhibitor that epigenetically modulates host cell responses, while DHA is a polyunsaturated fatty acid that directly interferes with viral membrane integrity. This composite approach creates a multi-faceted antiviral effect that is more reliable and effective than either component alone.
2Adaptability or versatility
If new antiviral agents are developed, then therapeutic options increase, but disease burden continues to exceed strategies
Solution Approach 1:
The VPA-DHA combination therapy is designed to be universally effective against multiple coronavirus variants. VPA's mechanism of increasing interferon expression provides broad-spectrum antiviral activity, while DHA's disruption of viral membranes is variant-independent. This universal approach addresses the adaptability need without being limited to specific viral strains, helping to control disease burden across diverse coronavirus infections.
3Reliability
If vaccination strategy is implemented, then prevention is attempted, but persistent effectiveness is unachievable
Solution Approach 1:
The VPA-DHA combination can be administered as prophylactic treatment before coronavirus infection occurs. VPA pre-treatment upregulates antiviral interferon expression in advance, creating a heightened state of cellular defense. DHA incorporation into cell membranes beforehand may also provide preemptive protection by making cells less susceptible to viral entry and replication. This preliminary action complements vaccination by providing an additional layer of immediate, actionable defense.
Data Source
AI summary
Disclosed herein, are methods for treating, preventing or inhibiting a coronavirus infection or a disease or condition associated with a coronavirus infection. The methods can comprise administering to the subject one or more therapeutically effective doses of valproic acid and docosahexaenoic acid.